Key result
Trimetazidine fails to alter myocardial external efficiency vs placebo in MYBPC3 or MYH7 carriers.
Why the study?
Pre-clinical HCM PV/LPV carriers have decreased myocardial external efficiency, but evidence that metabolic treatments correct this reduced efficiency is lacking.
Does trimetazidine improve myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant?
RCT (n=40)
Double-blind
Stratified for sex
Does trimetazidine improve myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant?
Answers are grounded in this paper and cite their sources.
In pre-clinical carriers of hypertrophic cardiomyopathy pathogenic variants, 8 weeks of trimetazidine therapy did not improve myocardial external efficiency compared to placebo.
AIMS: Previous studies have shown that individuals with a hypertrophic cardiomyopathy (HCM) pathogenic variant (PV) or likely pathogenic variant (LPV) without a HCM phenotype (PV/LPV carrier) have decreased myocardial external efficiency (MEE), which is thought to be a key pathomechanism in the onset and progression of HCM. Metabolic treatments improved exercise capacity in HCM patients, but evidence that such drugs correct reduced MEE is lacking. The ENERGY trial is a double-blind, placebo-controlled randomized clinical trial to define if the metabolic drug trimetazidine (TMZ) corrects reduced MEE in PV/LPV carriers for HCM. METHODS AND RESULTS: 51 MYBPC3 or MYH7 PV/LPV carriers were screened after which 40 were included and randomized into a treatment group (n = 20) or placebo group (n = 20) stratified for sex. Participants were treated with TMZ 20 mg or placebo three times daily during 8 weeks. The main outcome of this study was MEE as measured by [11C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan. Secondary outcomes were exercise parameters as measured by cardio-pulmonary exercise testing (CPET). Drug safety was monitored by (serious) adverse event registration. Treatment groups were comparable in terms of age, sex, body mass index, P/LP gene variant, and echocardiographic parameters without significant differences. Baseline CMR parameters and MEE were not significantly different between treatment groups. Eight weeks of treatment with TMZ did not significantly alter MEE compared to placebo. The mean MEE changed from 30.3 ± 3.8 to 29.8 ± 4.3% in the placebo group and from 30.1 ± 4 to 29.1 ± 4% in the TMZ group. Compared to placebo, the TMZ group did not have a significantly different MEE (difference -0.44, 95% interaction CI, -2.863 to 1.986, P = 0.68). The mean V'O2max as a percentage of predicted V'O2max (V'O2max %pred) changed from 108 ± 17 to 111 ± 19 (95% CI, -6 to 10, P = 0.84) percent in the placebo group and from 105 ± 17 to 113 ± 14 (95% CI, 1 to 16, P = 0.03) percent in the TMZ group. After adjustment for baseline, the TMZ group had a significantly increased V'O2max %pred (difference 6.37, 95% interaction CI, -3 to 16, P = 0.04). CONCLUSION: The ENERGY trial is the first proof-of-concept randomized controlled trial to test the hypothesis that TMZ improves MEE in MYBPC3 or MYH7 PV/LPV carriers. We conclude that metabolic therapy with TMZ may not correct the P/LP gene variant-related decrease in MEE. TRIAL REGISTRATION: Netherlands Trial Register NL7492 (URL https://onderzoekmetmensen.nl/nl/trial/25078).
No takes yet. Share an insight, caveat, or question.
Driel et al. (2025) conducted an RCT in Pre-clinical hypertrophic cardiomyopathy pathogenic variant carriers (n=40). Trimetazidine vs. Placebo was evaluated on Myocardial external efficiency (MEE) (Difference -0.44, 95% CI -2.863 to 1.986, p=0.68). Trimetazidine did not alter myocardial external efficiency compared to placebo in MYBPC3 or MYH7 PV/LPV carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: